Uncategorized

From, who joins the surgical robot developer from Aruna Bio, will take the reins from co-founder Adam Sachs on Aug. 7.

The medtech firm, which previously forecast a $200 million tariff impact for 2025, also raised its earnings outlook, citing strength in procedure demand.

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO Leonard Schleifer told investors.

Medicare finalized inpatient pay rates that are slightly higher than those proposed in April. Hospital groups were pleased with the increases, but said they were still inadequate.

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough programs on its hands.

A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

Wayne DeVeydt, a healthcare veteran who most recently worked at Bain Capital, will take up the finance chief job on Sept. 2 as the healthcare behemoth faces an array of operational challenges. 

The two countries will continue to negotiate over a 90-day period during which imports from Mexico will avoid a planned 30% tariff from the Trump administration. 

Cigna’s health insurance business is performing within expectations, even as the insurer faces persistently heightened medical costs, executives said.

In its first commercial quarter for ATTR-cardiomyopathy, Alnylam’s Amvuttra reached roughly 1,400 patients and made more than $490 million.